Company intelligence / Profile preview

Captura Biopharma

Ownership: Private
Development stage: Phase 1

Overview

C2E2 has completed IND-enabling studies and initial animal efficacy and safety testing. NIH and BARDA-funded animal trials have shown efficacy in decorporating select heavy metals such as americium and plutonium. Human Phase 1 trials are planned to determine dosing for pivotal animal studies required for regulatory approval under the FDA Animal Rule.[6][5]

Therapeutic areas: Other
Modalities: Small molecules (oral chelators)
Industry: Biotech

Drug pipeline

1 asset

C2E2

Unknown

Partnerships

NIH and BARDA funding/support for preclinical development[4][5]

Beyond the preview

Go deeper on Captura Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Captura Biopharma.

Explore the full profile